Individualization of therapy with hyperlipidemia agents
First Claim
Patent Images
1. A method of characterizing a multi-determinant metabolic phenotype for at least one hyperlipidemia agent, wherein a plurality of phenotypic determinants are identified as corresponding to respective metabolic characteristics;
- said method comprising;
a) administering to an individual a probe substrate specific to metabolic pathway(s) for said at least one hyperlipidemia agent;
b) detecting metabolites of said metabolic pathway(s) in a biological sample from said individual in response to said probe substrate; and
c) characterizing respective phenotypic determinants of said multi-determinant metabolic phenotype based on detected metabolites.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with hyperlipidemia agents.
-
Citations
113 Claims
-
1. A method of characterizing a multi-determinant metabolic phenotype for at least one hyperlipidemia agent,
wherein a plurality of phenotypic determinants are identified as corresponding to respective metabolic characteristics; - said method comprising;
a) administering to an individual a probe substrate specific to metabolic pathway(s) for said at least one hyperlipidemia agent;
b) detecting metabolites of said metabolic pathway(s) in a biological sample from said individual in response to said probe substrate; and
c) characterizing respective phenotypic determinants of said multi-determinant metabolic phenotype based on detected metabolites. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 110, 111, 112)
- said method comprising;
-
49. A method of using a multi-determinant metabolic phenotype to individualize a treatment regimen for at least one hyperlipidemia agent compound for an individual, wherein the multi-determinant metabolic phenotype of said individual is determined;
- a safe and therapeutically effective dose of said at least one hyperlipidemia agent compound treatment is determined and/or selected based on said multi-determinant metabolic phenotype of said individual.
- View Dependent Claims (50, 51, 52, 53, 54)
-
55. A method of treating an individual having a condition treatable with at least one hyperlipidemia agent compound, with at least one hyperlipidemia agent compound, said method comprising:
-
a) determining a multi-determinant metabolic phenotype of said individual; and
b) administering a safe and therapeutically effective dose of said at least one hyperlipidemia agent compound to said individual, wherein said dose has been determined based on a metabolic profile of said individual corresponding to said individual'"'"'s metabolic phenotype for said at least one hyperlipidemia agent compound as represented by said multi-determinant metabolic phenotype. - View Dependent Claims (56, 57, 58, 59, 60)
-
-
61. An assay system for detecting the presence of enzyme-specific metabolites in a biological sample, said sample obtained from an individual treated with a known amount of at least one probe substrate for at least one hyperlipidemia agent compound, specific for metabolic pathways of said metabolites, said assay comprising:
-
a) means for receiving said biological sample, including a plurality of affinity complexation agents contained therein;
b) means for detecting presence of said enzyme-specific metabolites bound to said affinity complexation agents; and
c) means for quantifying ratios of said metabolites to provide corresponding phenotypic determinants;
wherein said phenotypic determinants provide a metabolic phenotypic profile of said individual. - View Dependent Claims (62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 113)
-
-
73. A method of using an enzyme-specific assay for the individualization of treatment with at least one hyperlipidemia agent compound, which comprises:
-
a) conducting said assay to identify phenotypic determinants in a biological sample obtained from an individual treated with a probe substrate for said at least one hyperlipidemia agent compound;
b) determining a rate of drug metabolism according to said determinants; and
c) determining and/or selecting a safe and therapeutically effective dose of said class of Hyperlipidemia agents compounds for said individual based on said rate. - View Dependent Claims (74, 75, 76, 77, 78, 79, 80, 81, 82, 83)
-
-
84. A method of screening a plurality of individuals for participation in a drug treatment trial assessing the therapeutic effect of at least one hyperlipidemia agent compound, said method comprising:
a) selecting individuals having a metabolic phenotype characterized as effective for metabolizing said at least one hyperlipidemia agent compound. - View Dependent Claims (85, 86, 87, 88, 89)
-
90. A method of screening a plurality of individuals for treatment with at least one hyperlipidemia agent compound, said method comprising:
-
a) genotyping said individuals to identify individuals lacking at least one allelic variation known to prompt toxicity of said at least one hyperlipidemia agent compound; and
b) selecting individuals having a metabolic phenotype characterized as effective for metabolizing said at least one hyperlipidemia agent compound. - View Dependent Claims (91, 92, 93, 94, 95, 96, 97, 98, 99, 100)
-
-
101. A method of screening a plurality of individuals for participation in a drug treatment trial assessing the therapeutic effect of a candidate hyperlipidemia agent compound treatment, said method comprising:
-
a) genotyping each of said individuals to identify individuals lacking at least one allelic variation known to prompt the toxicity of said hyperlipidemia agent compound; and
b) characterizing a multi-determinant metabolic phenotype of said identified individuals of step a) to determine each individual'"'"'s ability to metabolize said hyperlipidemia agent compound. - View Dependent Claims (102, 103, 104, 105, 106, 107, 108, 109)
-
Specification